The role of furocoumarins in grapefruit juice/drug interactions. - PowerPoint PPT Presentation

1 / 53
About This Presentation
Title:

The role of furocoumarins in grapefruit juice/drug interactions.

Description:

... + Flavonoids 6,7-DHB Ultrafilration Debitter Ethyl Acetate Etute + EtOH +Flash Chromatography Conc. + EtOH + Flash Chromatography Clinical Test Juice ... – PowerPoint PPT presentation

Number of Views:138
Avg rating:3.0/5.0
Slides: 54
Provided by: PaulBW
Category:

less

Transcript and Presenter's Notes

Title: The role of furocoumarins in grapefruit juice/drug interactions.


1
The role of furocoumarins in grapefruit
juice/drug interactions.
  • Paul B. Watkins
  • University of North Carolina
  • Chapel Hill, N.C.

2
Grapefruit EffectOn Drug LevelsHas Sweeter
Side By SYLVIA PAGÁN WESTPHALNovember 27,
2007 Page D1 Wall Street Journal
3
King's doctor prescribed Lipitor, along with
continued diet and exercise. King obeyed. His
Lipitor dose was gradually increased to a high
dose of 60 milligrams a day. After four months,
he'd brought his LDL cholesterol down to 104.
He'd also lost 36 pounds. Later, King headed to
his winter home in Florida. With a grapefruit
tree on his patio, he drank two to three daily
glasses of fresh grapefruit juice. But just two
months after getting the good news about his
cholesterol, King was in a Florida emergency
room. His symptoms muscle pain that had started
suddenly, fatigue, and high fever. King was
diagnosed with rhabdomyolysis, a severe muscle
reaction that can cause death.
Web MD - 2005
4

Interpatient variation in pharmacokinetics

5
First Pass Metabolism
6
First Pass Metabolism
7
LOCATION OF INTESTINAL CYP3A4
Kolars et al. (1994) Pharmacogenetics 4247-59
8

9
Effect of Grapefruit juice on serum levels of a
some drugs

10
Some drugs influenced by grapefruit juice
  • Drug AUC increase
  • felodipine 3 fold
  • cisapride 1.4 fold
  • cyclosporine 1.5 fold
  • saquinavir 2 fold
  • terfenadine 2.5 fold
  • buspirone 9 fold
  • lovastatin/simvastatin 10 fold

11
(No Transcript)
12
8/30/02 email .. our business outlook has
been greatly challenged by the grapefruit - drug
interaction and the way it is being communicated
(often inaccurately) to the public Jay
Dravenstadt Manager RD, Grapefruit Business
Ocean Spray Cranberries Lakeville-Middleboro,
MA 02349

13
  • Hypothesis

Grapefruit juice interactions are not clinically
important because intestinal CYP3A4 is
upregulated (induced) in people who regularly
drink the juice.
14
  • Clinical Study

10 healthy adults were admitted to the GCRC
and received one glass of grapefruit juice (8
oz) with each meal for 7 days Endoscopy with
pinch biopsies performed before and
after. Biopsy content of CYP3A4 protein and
mRNA measured
15
GFJ REDUCESINTESTINAL CYP3A4 PROTEIN
GFJ reduced CYP3A4 protein content in all
subjects
Lown et al. (1997) JCI 992545-53
16
  • Conclusions

Hypothesis is completely wrong. GFJ makes CYP3A4
go away!
17
Screening HLPC fractions (Fraction C) for ability
to inhibit CYP3A4 in human intestinal microsomes
18
Furocoumarins in Grapefruit Juice
O
H
O
O
O
H
O
O
O
O
O
O
6,7-dihydroxybergamottin (DHB)
Bergamottin
O
H
O
O
O
H
O
H
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
FC708
FC726
19
Caco-2 Cells
  • Derived from a human colon adenocarcinoma
  • Upon differentiation resemble small intestinal
    enterocytes
  • In the presence of 1a,25-(OH)2-D3 express CYP3A4
  • Schmiedlin-Ren et al. Mol Pharmacol 51 741-754,
    1997

Basolateral medium
insert
apical medium
culture dish
Caco-2 cell monolayer
20
Time course of the effect of DHB on CYP3A4
CYP3A4
0 hr
1 hr
2 hr
3 hr
4 hr
8 hr
1 hr
2 hr
3 hr
4 hr
8 hr
12 hr
12 hr
0.5 hr
0.5 hr
3A4 Standards
DHB
Vehicle
Unpublished data
21
  • Is this decrease in CYP3A4 protein content due to
    decreased rate of synthesis or accelerated rate
    of degradation?

22
Pulse Chase
Culture Medium
Protein Synthesis
23
Effect of DHB on the Degradation of CYP3A4
(Pulse Chase 35S labeled Met/Cys)
CYP3A4
0
0.5
1
2
4
8
12
24
48
DHB
Vehicle
Unpublished data
24
Ubiquitin- Proteasome Pathway
DDEP
P450 Inactivation
DDEP
Proteasome
25
Summary
Proteasome
26
Summary
  • DHB accelerates the rate of CYP3A4 degradation
    while having no effect on the rate of its
    synthesis
  • This results in a fall in CYP3A4 half life from
    14h to 3 h.

27
Modeling single administration GFJ effect for
dose and time course
Takanaga, et al, Br. J. Clin Pharmacol.
49,49,2000.
28
gut lumen  
 
enterocyte  
into the body  
29
Gut lumen  
 
enterocyte  
Into the body  
30
Gut lumen  
enterocyte  
 
X
Into the body  
31
Gut lumen  
enterocyte  
 
Into the body  
32
Where is this research headed?
  • 1). Development of new tools for human research

2). Improvements in oral drug delivery
3). New grapefruit juice
33
(No Transcript)
34
Saquinavir
  • 1). Most widely used HIV protease inhibitor

2). Oral availability 4-14
3). Very rapid metabolism by CYP3A4
35
Effect of SOJ on AUC of Saquinavir
JPET 308941-948, 2004
36
Where is this research headed?
  • 1). Development of new tools for human research

2). Improvements oral drug delivery
3). New grapefruit juice
37
Range of variation in enterocyte CYP3A4 content
in adults
  • 10

0
38

Variation in enterocyte CYP3A4 activity and the
oral disposition of some substrates
  • 10

0
39
Conclusion
  • Grapefruit juice / drug interactions are of
    minimal importance because dramatic increases in
    oral availability only occur in those patients
    who have very low oral availability at baseline

40
Effect of GFJ on Cisapride

Gross et al, CPT 65395,1999
41
In Florida, Bioavailability Systems LLC, a small
biotechnology company, claims to have purified
the grapefruit compounds responsible for the
boosting effect and has been able to improve the
blood levels of an anti-HIV drug. "This is
definitely a lemons to lemonade story," says
James Harris, founder and chief scientific
officer of the company. November 27,
2007 Page D1 Wall Street Journal
42
Reasons why grapefruit juice/drug interactions
shouldnt be very important
1). Susceptible drugs must have excellent
safety profile despite large interpatient
variation in exposure. 2). People with very
low intestinal CYP3A4 activity will be
encountered in clinical trials.
43
Situations where grapefruit juice/drug
interactions may rarely become clinically
significant
1). Patient is requiring higher than usual dose
of susceptible drug and begins drinking
juice for the first time. 2). Patient has
severe liver disease. 3). Patient has a
peculiar susceptibility to an adverse effect.
44
Where is this research headed?
  • 1). Development of new tools for human research

2). Improvements oral drug delivery
3). New grapefruit juice
45
(No Transcript)
46
(No Transcript)
47
Elimination of Furanocoumarins from GFJ
Juice
Retentate
Ultrafilration
Ethyl Acetate
Serum
Pectin Cellulose
Furanocoumarins Flavonoids
Debitter
Absorbed
Debittered Serum
Conc. EtOH Flash Chromatography
Etute EtOH Flash Chromatography
FC
Flavonoids
6,7-DHB
Flavonoids
Clinical Test Juice
Commercial FCF Flavor Package
48
Felodipine study design
  • 18 subjects brought to GCRC
  • Three-way randomized crossover design.
  • 10 mg sustained-release tablet of felodipine
    (Plendil) given with OJ, GFJ, or FC-free GFJ.
  • Blood samples (10-mL) collected at 0, 0.5, 1,
    1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours.

49
Felodipine interaction study
Felodipine (nM)
Time (hours)
n 18
Am. J. of Clin. Nutr. 83(5)1097-105, 2006
50
Conclusion
  • 1). It is possible to remove major FCs from
    grapefruit juice.
  • 2). This may not remove all GFJ / drug
    interactions.

51
gut lumen  
 
enterocyte  
into the body  
52
One such compound called naringin affects the
efficacy of the popular allergy drug Allegra by
blocking these transporters. "Even a normal glass
of juice will reduce the effects of Allegra by
half," says Dr. Bailey, whose team made the
discovery last year. "It's the tip of the
iceberg," he adds. "Big pharma is very
interested." November 27, 2007 Page D1 Wall
Street Journal
53
Thanks
  • Mary Paine, PhD. Shefali Malhotra
  • Anne Criss Susan Pusek
  • Stephane Mouly

Florida Dept of Citrus Bill Widmer, Ph.D. Bill
Stinson,Ph.D.
National Institutes of Health General Medical
Sciences R37-38149 General Clinical Research
Centers (NCRR).
Write a Comment
User Comments (0)
About PowerShow.com